MedTrace Logo

Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder

NCT01018992 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 267

Last updated 2017-03-07

Study results available
· View outcomes & findings →

Summary

This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).

Conditions

  • Stress Disorders, Post-Traumatic

Interventions

DRUG

GSK561679

GSK561679, oral administration, 350mg/day, 6 week administration

DRUG

Placebo

Matching placebo, oral administration, 1 pill/day for 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Boadie Dunlop, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018992 on ClinicalTrials.gov